Vicore Pharma Holding AB Statistics
Want to see SE:VICO full AI Analyst Report?
Vicore Pharma Holding AB (VICO) Stock Statistics & Valuation Metrics
Total Valuation
Vicore Pharma Holding AB has a market cap or net worth of SEK 3.02B. The enterprise value is SEK 1.93B.
- Market Cap
- SEK 3.02B
- Enterprise Value
- SEK 1.93B
Share Statistics
Vicore Pharma Holding AB has 281,644,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 281,644,500
- Owned by Insiders
- ―
- Owned by Institutions
- 6.02%
Financial Efficiency
Vicore Pharma Holding AB’s return on equity (ROE) is -0.44 and return on invested capital (ROIC) is -41.20%.
- Return on Equity (ROE)
- -0.44
- Return on Assets (ROA)
- -0.39
- Return on Invested Capital (ROIC)
- -41.20%
- Return on Capital Employed (ROCE)
- -0.41
- Revenue Per Employee
- 82.98K
- Profits Per Employee
- -10.38M
- Employee Count
- 46
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Vicore Pharma Holding AB is -5.65. Vicore Pharma Holding AB’s PEG ratio is -0.36.
- PE Ratio
- -5.65
- PS Ratio
- 781.36
- PB Ratio
- 4.14
- Price to FCF
- -8.89
- Price to Operating Cash Flow
- -6.09
- PEG Ratio
- -0.36
Income Statement
In the last 12 months, Vicore Pharma Holding AB had revenue of 3.82M and earned -477.47M in profits. Earnings per share was -1.99.
- Revenue
- 3.82M
- Gross Profit
- 3.82M
- Operating Income
- -454.44M
- Pretax Income
- -477.47M
- Net Income
- -477.47M
- EBITDA
- -477.41M
- Earnings Per Share (EPS)
- -1.99
Cash Flow
In the last 12 months, operating cash flow was -492.50M and capital expenditures 355.04M, giving a free cash flow of -336.58M billion.
- Operating Cash Flow
- -492.50M
- Free Cash Flow
- -336.58M
- Free Cash Flow per Share
- -1.19
Dividends & Yields
Vicore Pharma Holding AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -11.25%
- Earnings Yield
- -17.10%
Stock Price Statistics
- Beta
- 0.75
- 52-Week Price Change
- 6.63%
- 50-Day Moving Average
- 9.77
- 200-Day Moving Average
- 10.61
- Relative Strength Index (RSI)
- 61.47
- Average Volume (3m)
- 1.18M
Important Dates
Vicore Pharma Holding AB upcoming earnings date is Feb 25, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Vicore Pharma Holding AB as a current ratio of 10.31, with Debt / Equity ratio of 0.00%
- Current Ratio
- 10.31
- Quick Ratio
- 10.31
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.21
- Interest Coverage Ratio
- -9.03
Taxes
In the past 12 months, Vicore Pharma Holding AB has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Vicore Pharma Holding AB EV to EBITDA ratio is -4.59, with an EV/FCF ratio of -7.71.
- EV to Sales
- 677.95
- EV to EBITDA
- -4.59
- EV to Free Cash Flow
- -7.71
- EV to Operating Cash Flow
- -5.27
Balance Sheet
Vicore Pharma Holding AB has SEK 771.99M in cash and marketable securities with SEK 0.00 in debt, giving a net cash position of SEK 771.99M billion.
- Cash & Marketable Securities
- SEK 771.99M
- Total Debt
- SEK 0.00
- Net Cash
- SEK 771.99M
- Net Cash Per Share
- SEK 2.74
- Tangible Book Value Per Share
- SEK 2.57
Margins
Gross margin is 100.00%, with operating margin of -14161.60%, and net profit margin of -13397.10%.
- Gross Margin
- 100.00%
- Operating Margin
- -14161.60%
- Pretax Margin
- -13390.33%
- Net Profit Margin
- -13397.10%
- EBITDA Margin
- -14756.35%
- EBIT Margin
- -14756.35%
Analyst Forecast
The average price target for Vicore Pharma Holding AB is SEK 39.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- SEK 39.00
- Price Target Upside
- 267.23% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- -54.97%
- EPS Growth Forecast
- -1.66%
Scores
- Smart Score
- ―
- AI Score
- 53

